How effective is osimertinib mesylate tablets?

Osimertinib mesylate tablets (Osimertinib), as a targeted therapy, has shown significant therapeutic effects on patients with EGFR gene mutation-positive non-small cell lung cancer (NSCLC). The following are the main aspects about the effect of mesylateosimertinib/osimertinib tablets:

1.Prolong progression-free survival time (PFS): Clinical trials have shown that osimertinib mesylate tablets can significantly extend the progression-free survival time of patients compared with traditional EGFR inhibitors in first-line treatment. PFS is one of the important indicators to measure the effect of tumor treatment. Prolonging PFS means that tumor growth is slowed down, and patients can survive longer without disease progression.

2.Improve overall survival time (OS): Although the improvement in overall survival time in some clinical trials is not significant, osimertinib mesylate tablets still show certain OS advantages in first-line treatment. For drug resistance treatment, Osimertinib mesylate/osimertinib tablets can also significantly prolong the overall survival time of patients.

3.Improving the objective response rate (ORR): Osimertinib has a higher objective response rate in both first-line treatment and drug-resistant treatment. This means that after the patient receives treatment, the tumor lesions shrink or disappear, and the tumor control effect is significant.

4.The treatment effect of brain metastasis is good: Brain metastasis is a common clinical problem in patients with advanced NSCLC, and osimertinib mesylate tablets have good permeability in the brain and can effectively inhibit the growth and spread of brain metastasis lesions, providing patients with an effective treatment option for brain metastasis.

5.Reducing symptoms and improving quality of life: In addition to its direct anti-tumor effect, mesylateosimertinib tablets can also reduce tumor-related symptoms, such as dyspnea, cough, etc., and improve patients' quality of life.

In general, Osimertinib mesylate tablets, as a targeted therapy, have shown significant effects in the treatment of NSCLC. It can prolong the progression-free survival time of patients, increase the objective response rate, improve overall survival time, and has a good therapeutic effect on brain metastases. In addition, Osimertinib mesylate tablets can also reduce symptoms and improve patients' quality of life. However, patients still need to be closely monitored during treatment and deal with possible adverse reactions in a timely manner to ensure the safety and effectiveness of the treatment.